Context — PDAC

The Psychopharmacological Drugs Advisory Committee meetings that recommended the licensing of Prozac, and Zoloft, and then considered the issue of Prozac and suicide are listed here. These committee meetings dealt with issues of profound importance. In the case of both Prozac and Zoloft, it is clear that many committee members were troubled by the lack of convincing evidence for the efficacy of these drugs. In the case of the suicide issue, there was a clear calculus to be considered – would more people die as a result of warnings than might die if Prozac was left without warnings about suicidality?

Click on file below for transcript. These are large PDF documents, so patience may be needed.

• Prozac OCT 85
• Prozac SEPT 91
• Zoloft NOV 90